J&J strikes deal with Emergent BioSolutions on coronavirus vaccine manufacturing

Michelle K. Wallace

(Reuters) – Johnson & Johnson (JNJ.N) said on Thursday it had struck a deal with Emergent BioSolutions Inc (EBS.N) to use its manufacturing facilities to help in an effort to make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus.

The U.S. healthcare conglomerate said the deal was the first in a series of prospective global partnerships to accelerate manufacturing of its experimental COVID-19 vaccine candidate, even before it has a signal that it works.

J&J plans to start human testing by September, with an eye on having it ready under an emergency use authorization in early 2021, far quicker than the typical 18-month period that it takes for vaccines to be tested, approved and then manufactured.

Under the deal, valued at about $135 million, Emergent said it would provide drug substance manufacturing services and was reserving large-scale manufacturing capacity.

J&J and the U.S. government are investing $1 billion to create enough manufacturing capacity for the experimental vaccine candidate to stop the virus that has killed nearly 185,000 people around the globe.

Reporting by Uday Sampath in Bengaluru; Editing by Subhranshu Sahu

Source Article

Next Post

Brokerages tell clients - no buying oil for two months

(Reuters) – Several brokerages, including discount giant TD Ameritrade Corp (AMTD.O) are restricting customers from buying new positions in certain crude oil contracts after an unprecedented sell-off that sent prices below negative-$40 on Monday. FILE PHOTO: Crude oil storage tanks are seen in an aerial photograph at the Cushing oil […]